Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Share Options

31 Aug 2011 14:44

RNS Number : 3548N
Angle PLC
31 August 2011
 



For immediate release

31 August 2011

 

ANGLE plc ("the Company")

 

Share Options

 

Reflecting the current developments within the business and the need to ensure ongoing incentivisation of the management team, the Remuneration Committee has cancelled certain existing share options over ordinary shares in the Company issued to staff and directors and issued new share options at the current market price.

 

Following the cancellation of 940,422 existing share options and the issue of 1,856,000 new share options, the Company now has outstanding options issued to staff and directors over a total of 2,055,397 ordinary shares being 5.8% of the shares currently in issue.

 

The exercise price for the new share options is set at the current mid market price of 25.75 pence per share. Vesting of the share options will be subject to a performance condition that the share price together with any dividend payments has risen by at least 50% from the current market price. The share options will vest over a three year period and expire ten years after issue.

 

Following the new issue of share options, the total number of share options held by the directors and senior management of the Company are:

 

Options (% issued)

Before issue

After issue

Increase

Andrew Newland, Chief Executive

648,675 (1.8%)

950,000 (2.7%)

301,325 (0.8%)

Ian Griffiths, Finance Director

247,619 (0.7%)

500,000 (1.4%)

252,381 (0.7%)

Shane Booth, Parsortix CEO

33,810 (0.1%)

250,000 (0.7%)

216,190 (0.6%)

 

 

The non-executive directors do not hold share options.

 

ANGLE Chairman, Garth Selvey, commented:

"The new options are part of a revitalised remuneration scheme which takes account of changes within the Company and replace four sets of options awarded between 2005 and 2007. The new options also take into account salary waived by senior members of the Company."

 

 

For further information:

ANGLE plc

01483 685830

Garth Selvey, Chairman

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

Collins Stewart Europe Limited

Matt Goode

0207 523 8350

Buchanan

Lisa Baderoon, Catherine Breen

020 7466 5000

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee

0207 653 0030

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDKDDQNBKDNFN
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.